Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe in heart transplantation: initial experience.

J Moro1, L Almenar, L Martínez-Dolz

  • 1Heart Failure and Transplant Unit, Department of Cardiology, La Fe University Hospital, Valencia, Spain. moro@uv.es

Transplantation Proceedings
|September 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Situation and Prognostic Evolution of Combined Heart-lung Transplantation in a European Union Country.

International journal of organ transplantation medicine·2023
Same author

Shortening replacement by emulsion and foam template hydroxypropyl methylcellulose (HPMC)-based oleogels in puff pastry dough. Rheological and texture properties.

Current research in food science·2023
Same author

Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation.

Journal of microbiological methods·2023
Same author

Associations of serum sclerostin levels with body composition, pulmonary function, and exacerbations in COPD patients.

Pulmonology·2022
Same author

Rheological properties of emulsion templated oleogels based on xanthan gum and different structuring agents.

Current research in food science·2022
Same author

In vivo hydrogen peroxide diffusivity in brain tissue supports volume signaling activity.

Redox biology·2022
Same journal

Living Donor Kidney Transplantation: Comparison of Graft Survival Between First and Second Transplants-A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
See all related articles

Adding ezetimibe to statin therapy effectively controlled dyslipidemia in heart transplant recipients. This combination demonstrated an excellent safety profile, improving lipid management in these patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Dyslipidemia is a prevalent risk factor in heart transplant (HT) recipients, often worsened by immunosuppressive medications.
  • Statins are commonly used for dyslipidemia in HT patients, but treatment efficacy can be suboptimal for some.
  • Ezetimibe offers a complementary mechanism of action by inhibiting enterohepatic recirculation of cholesterol.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding ezetimibe to existing statin therapy in heart transplant recipients with suboptimal lipid control.

Main Methods:

  • A study included 19 stable heart transplant patients on statin therapy with uncontrolled cholesterol levels.
  • Lipid profiles, cyclosporine levels, and liver function tests were assessed at baseline (statins only) and after 6 months of adding ezetimibe (10 mg/day).

Related Experiment Videos

  • Statistical analysis utilized Student's t test for paired samples to compare baseline and post-treatment values.

    • Main Results:

    • Addition of ezetimibe significantly reduced total cholesterol (279 to 198 mg/dL, P=.0001) and LDL-cholesterol (171 to 109 mg/dL, P=.001).
    • No significant differences were observed in other measured variables, including triglycerides, cyclosporine levels, and liver enzymes.
    • The patient cohort was predominantly male (95%), with a mean age of 59 years and a mean time since HT of 7 years.

    Conclusions:

    • Combining ezetimibe with statin therapy is an effective strategy for managing dyslipidemia in heart transplant recipients.
    • This combination therapy exhibited a favorable safety profile in the studied population.